GSK vs SNY
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 04, 2026
GSK
SNY
Investment Advisor Scores
SNY
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | SNY | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 9.7943 | 9.4429 | SNY |
| PEG Ratio | 6.1233 | 31.4621 | GSK |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 4.0% | 15.7% | SNY |
| Earnings Growth | -22.8% | 9.4% | SNY |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 48.0/100 | 36.5/100 | GSK |
| Profit Margin | 13.0% | 8.2% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | EXTENDED | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
NeutralMixed signals - no dominant trend phase, RSI 54
SNY
NeutralMixed signals - no dominant trend phase, RSI 77
Fundamentals Snapshot
| Metric | GSK | SNY |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.2 | 8.9 |
| Trailing P/E | 17.9 | 24.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.2% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.3% | 0.3% |
| EPS | 2.87 | 2.01 |
| Dividend Yield | 0.04% | 0.00% |